Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

BACKGROUND. The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET rearrangements; and MET amplification. We investigated the feasibility and utility of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Suh, James H., Johnson, Adrienne, Albacker, Lee, Wang, Kai, Chmielecki, Juliann, Frampton, Garrett, Gay, Laurie, Elvin, Julia A., Vergilio, Jo-Anne, Ali, Siraj, Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2016
Pynciau:
Lung Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912374/
https://ncbi.nlm.nih.gov/pubmed/27151654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0030
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg